Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06782048 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Use of Pyrvinium to Reverse Stomach Precancerous Conditions

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Aug 2025 to Nov 2026
    • Eligibility criteria expanded, about 169 words
    • Study description expanded, about 26 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is carried out to find out if a drug called pyrvinium is able to convert pre-cancerous tissue in the stomach back to healthy tissue, to lower the chances of stomach cancer. Pyrvinium is a drug that has been used for a long time to treat pinworms in children and its anti-cancer properties are currently under investigation. Tests in animals have shown that pyrvinium made unhealthy tissue healthier and stopped some cells from growing in a bad way. Based on preclinical studies, the investigators hypothesise that the proportion of samples with pre-cancerous tissue in the stomach would decrease by 30% after exposure to pyrvinium at the 6-week timepoint, with anticipated durability of the response at the one-year follow-up.
Trial Details
NCT Number NCT06782048
Lead Sponsor National University Hospital, Singapore
Collaborators: National University of Singapore, Vanderbilt University Medical Center
Conditions
(from sponsor)		 STOMACH NEOPLASM
Related terms Stomach Neoplasms
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov